This paper addresses a topic which I've long confronted - see my talk at the last TUK conference in Meriden. One cannot compare results from different labs if the methods of measurement used do not very closely agree with each other. This need has long been addressed by the Thienpont group but its implimentation by the various FT4 test manufacturers is slow or nonexistent, owing to the cost of recalibration and resubmission to regulatory authorities, with no discernible financial benefit. But if the field is to be more rationalised, this must occur, if necessary by regulatory force.
Free thyroxine measurement in clinical practice: how to optimize indications, analytical procedures, and interpretation criteria while waiting for global standardization
October 2022
Critical Reviews in Clinical Laboratory Sciences
DOI: 10.1080/10408363.2022.2121960
Federica D'Aurizio, Jürgen Kratzsch. Damien Gruson, Luca Giovanella
Written by
diogenes
Remembering
To view profiles and participate in discussions please or .
About twenty years ago, the FDA required all USA levothyroxine products to re-apply for approval as if they were new medicines. (Due to their continual appearance in recalls and deep questions over switching products.)
Perhaps the approval authorities need to act, hopefully in concert, to require the companies to re-apply for approval?
That was quite an interesting read. I didn't understand most of it, but I got the gist of it.
"Indeed, in a survey of 13 FT4 methods, more than 50% of the results in four of the methods did not meet the allowable inaccuracy criteria" Well, that's not really a surprise is it.
"Notably, patient-related factors such as changes in thyroid hormone receptor sensitivity, age, and sex add further complexity to the challenge of establishing specific RIs for patients treated with levothyroxine. In practice, it is preferable to monitor TSH levels in this population and to use FT4 measurement only in patients with central hypothyroidism." I have only 3 words to express my thoughts on this recommendation........Just F Off
“In practice, it is preferable to monitor TSH levels in this population and to use FT4 measurement only in patients with central hypothyroidism."
the absurdity continuum 😱
Totally agree nellie237 - if I had been subjected to that practice I would have been grossly under medicated and very ill (still). Was bad enough being mismanaged at the start.
Yes, whilst criticising tests for inconsistency, it was a fatally false step to take the conventional view that, because the tests were together as a class unsatisfactory, one should fall back on TSH. That's the outmoded view of present day thinking. The return of the art of diagnosis and treatment is not yet upon us.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Direct measurement of T3 likely vital say researchers
On the Clinical Diagnosis and Treatment of Hypothyroidism
